Every Form 4 that Medifast, Inc. (MED) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MED and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MED filings page.
MEDIFAST INC (MED) director Parsa Kiai reported two indirect open-market purchases of MED common stock on 2026-08-26 totaling 43,150 shares at an average price of $12.2632 per share. The shares are held through Steamboat Capital funds and related entities, and Kiai disclaims beneficial ownership except to the extent of his pecuniary interest.
MEDIFAST INC (MED) director Kiai Parsa reported indirect open-market purchases of MED common stock on August 24, 2026. Entities associated with him bought 4,329 shares in total at an average price of $11.9996 per share, with actual prices ranging from $11.99 to $12. The purchases were made through Steamboat Capital-related funds, and Parsa may be deemed to have a pecuniary interest in those shares, while disclaiming beneficial ownership beyond that interest.
MEDIFAST INC (MED) director Parsa Kiai reported indirect open-market purchases of MED common stock on August 19–20, 2026. Entities associated with him bought a total of 72,487 shares at weighted-average prices of $11.6576 and $11.6037 per share. The positions are held by Steamboat Capital funds, over which affiliated entities have investment discretion. Kiai may be deemed to have a pecuniary interest in these shares but disclaims beneficial ownership except to that extent. The trades were not reported as made under a Rule 10b5-1 trading plan.
Rose Jeffrey Matthew reported acquisition or exercise transactions in this Form 4 filing.
Medifast Inc director Jeffrey Matthew Rose reported equity-based compensation rather than open-market trading. On May 26, 2026, he received two awards of common stock with no cash price per share, both classified as grants or awards.
The filing shows an award of 6,739 shares of common stock, described in the footnotes as restricted stock units granted under Medifast’s Director's Deferred Compensation Plan in connection with annual director fees. Each unit represents one share and will vest in full on May 26, 2027.
A separate entry reports an additional 11,680 shares of common stock received as a grant or award. The footnotes explain that Rose elected to receive Medifast common stock in lieu of cash compensation for his annual service as a non-employee director. Following these transactions, his reported direct holdings include 18,419 shares in one line and 11,680 shares in another.
MEDIFAST INC director Kiai Parsa reported equity-based compensation awards rather than open-market trades. On May 26, 2026, he received 7,637 restricted stock units and a separate grant of 11,680 shares of common stock at no cash cost, in connection with his annual director fees.
According to the company’s Director's Deferred Compensation Plan, each unit represents one share of common stock, granted from the Amended and Restated 2012 Share Incentive Plan, and these shares will vest in full on May 26, 2027. The filing shows direct holdings associated with these awards of 19,317 and 11,680 shares, respectively, underscoring that this is a compensation-related acquisition, not a market purchase or sale.
Thomas Andrea B reported acquisition or exercise transactions in this Form 4 filing.
MEDIFAST INC director Andrea B. Thomas received an equity grant of 11,680 restricted stock units as part of annual director fees. The award was made under the company’s Director's Deferred Compensation Plan, with each unit representing one share of common stock. The RSUs, issued from the Amended and Restated 2012 Share Incentive Plan, will vest in full on May 26, 2027. Following this grant, Thomas directly holds 35,697.123 shares of Medifast common stock.
SCHLACKMAN SCOTT reported acquisition or exercise transactions in this Form 4 filing.
Medifast Inc. director Scott Schlackman received an award of 11,680 restricted stock units as part of his annual director fees. Each unit represents one share of common stock granted under the company’s share incentive plan and is scheduled to vest in full on May 26, 2027. Following this grant, Schlackman directly holds 42,228.707 shares of common stock.
Geary Elizabeth A. reported acquisition or exercise transactions in this Form 4 filing.
Medifast Inc. director Elizabeth A. Geary received a grant of 11,680 restricted stock units of common stock as part of her annual director fees under the company’s Director's Deferred Compensation Plan. The award was made at a grant price of $0.00 per share.
Each unit represents one share of Medifast common stock and will vest in full on May 26, 2027, subject to the plan terms. Following this grant, Geary’s reported direct holdings total 31,225 shares of Medifast common stock, reflecting routine, compensation-related equity issuance rather than an open-market purchase.
Xian Ming reported acquisition or exercise transactions in this Form 4 filing.
Medifast Inc. director Xian Ming received an annual grant of 11,680 cash-settled restricted stock units under the 2012 Share Incentive Plan. These units will vest in full on May 26, 2027, and each represents a right to receive the cash value of one share of common stock at vesting.
After this grant, Ming’s reported derivative holdings tied to common stock total 43,822.918 units. This is a compensation award, not an open-market stock purchase or sale.
Medifast Inc. director Scott Schlackman reported open-market purchases of company stock. He bought 2,500 shares of Common Stock on May 8, 2026 at $12.65 per share and another 2,500 shares on May 11, 2026 at $12.53 per share. These transactions total 5,000 shares and were classified as open-market purchases. Following the later transaction, Schlackman directly owns 30,548.707 shares of Medifast Common Stock.
Medifast Inc. VP, Finance & CAO Jonathan Barrett MacKenzie reported compensation-related stock activity. On March 25, 2026, he received a grant of 10,830 shares of common stock as restricted stock units under the 2012 Share Incentive Plan, which will vest in three equal annual installments beginning on the first anniversary of the grant date.
To cover withholding taxes upon vesting of restricted stock unit grants, the issuer withheld a total of 1,130 shares of common stock across three transactions on March 13, 17, and 25, 2026, at prices between $9.59 and $10.05 per share. These tax-withholding dispositions were not open-market sales. Following these transactions, MacKenzie directly owned 20,838 shares of Medifast common stock.
MEDIFAST INC Chief Financial Officer James P. Maloney reported routine equity compensation and related tax withholding transactions. On March 25, 2026, he received 34,344 restricted stock units that vest in three equal annual installments and 1,014 shares issued upon vesting of performance stock units earned under prior performance criteria.
To cover withholding taxes tied to vesting events, shares were automatically withheld on several dates: 3,224 shares at $9.59 per share and 482 shares at $10.05 per share, plus 918 shares at $9.62 per share. These F-code transactions reflect tax payments rather than open-market sales. After these awards and withholdings, Maloney directly holds 73,033 shares of Medifast common stock.
Medifast (MED) Chairman & CEO Daniel R. Chard reported a mix of equity awards, tax withholdings, and an open-market share purchase. On March 20, 2026, a joint account for Chard and his spouse bought 17,678 shares of common stock at a weighted average price of $10.11 per share, with trades ranging from $10.04 to $10.18.
On March 25, 2026, Chard received 36,968 restricted stock units that vest in three equal annual installments and 4,827 shares issued upon vesting of earlier performance stock units. To cover withholding taxes on vesting events, the company withheld a total of 29,808 shares across several dates, which are recorded as tax-withholding dispositions rather than open-market sales.
Following these transactions, Chard directly holds 188,233 common shares. He also has indirect holdings, including 17,678 shares in a joint account with his spouse and 149,698.352 shares held by The Dan and Allyson Family Irrevocable Trust, where he serves as settlor and investment trustee.